Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Dana-Farber 2022 Scientific Symposium (Livestream)

  • Dana-Farber 2022 Scientific Symposium - online

  • In honor of the 75th anniversary of Dana-Farber Cancer Institute, we were thrilled to present a full-day scientific symposium. The morning session highlighted the past, present, and future of cancer research at Dana-Farber, and the afternoon session focused on our scientific legacy and the impact of mentorship on research at Dana-Farber.

    Date/Time: Thursday, September 29, 2022. 9:00 a.m. – 4:00 p.m.

    Watch the Symposium

    This event has concluded. Links to both sessions are now available to watch at your convenience:

    Morning Session
    Afternoon Session

    Agenda

    9:00 a.m. Morning Session: Past, Present, and Future of Cancer Research at Dana-Farber

    • Opening Remarks – Laurie H. Glimcher, MD, President and CEO, Dana-Farber Cancer Institute, and Richard and Susan Smith Professor of Medicine, Harvard Medical School
    • The Evolution of Basic Cancer Research at Dana-Farber – Barrett Rollins, MD, PhD, Chief Scientific Officer Emeritus, and Linde Family Professor of Medicine, Harvard Medical School
    • Bench to Bedside at Dana-Farber – William C. Hahn, MD, PhD, Executive Vice President and Chief Operating Officer, and William Rosenberg Professor of Medicine, Harvard Medical School
    • Impact of Dana-Farber on Pediatric Cancer – Scott Armstrong, MD, PhD, Chair, Department of Pediatric Oncology, Dana-Farber Cancer Institute, President, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, and David G. Nathan Professor of Pediatrics, Harvard Medical School
    • Dana-Farber from a Patient Perspective – Chloe Hall, Co-chair, Pediatric Patient and Family Advisory Council (PFAC)

    • Break: 10:20 – 10:40 a.m.

    • My Dana-Farber Journey: Serendipity, Science, and Success – Kornelia Polyak, MD, PhD, Professor of Medicine, Harvard Medical School
    • Evolution of Precision Medicine – Bruce Johnson, MD, Institute Physician, Dana-Farber Cancer Institute, ASCO Translational Research Professor, and Professor of Medicine, Harvard Medical School
    • Dana-Farber from a Patient Perspective – Jenny Dahlstein, Co-chair, Adult Patient and Family Advisory Council (PFAC)
    • Future of Research at Dana-Farber – Laurie H. Glimcher, MD, President and CEO, Dana-Farber Cancer Institute, and Richard and Susan Smith Professor of Medicine, Harvard Medical School

    12:00 p.m. Lunch break

    1:00 p.m. Afternoon Session: Scientific Legacy at Dana-Farber

    • The Legacy of David Livingston and Research in the DeCaprio Lab – James A. DeCaprio, MD, Professor of Medicine, Harvard Medical School, and Chief, Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute
    • The Legacy of Stanley Korsmeyer and Research in the Danial Lab – Nika Danial, PhD, Associate Professor, Harvard Medical School
    • Research in the Chouchani Lab – Edward Chouchani, PhD, Associate Professor, Harvard Medical School (trainee of Bruce Spiegelman, PhD)
    • Research in the Mills Lab – Evanna Mills, PhD, Assistant Professor, Harvard Medical School (trainee of Edward Chouchani, PhD)
    • Research in the Stegmaier Lab – Kimberly Stegmaier, MD, Vice Chair of Pediatric Oncology Research, Dana-Farber Cancer Institute, Ted Williams Investigator, Dana-Farber Cancer Institute, and Professor of Pediatrics, Harvard Medical School (trainee of Todd Golub, MD)

    • Break: 2:25 – 2:45 p.m.

    • Research in the Losman Lab – Julie-Aurore Losman, MD, PhD, Assistant Professor of Medicine, Harvard Medical School, and Associate Physician of Medicine, Brigham and Women's Hospital (trainee of William G. Kaelin Jr., MD)
    • Research in the Barbie Lab – David Barbie, MD, Associate Professor of Medicine, Harvard Medical School (trainee of William C. Hahn, MD, PhD)
    • Research in the Ghobrial Lab – Irene Ghobrial, MD, Professor of Medicine, Harvard Medical School, Lavine Family Chair of Preventative Cancer Therapy, and Director, Center of Prevention of Progression of Blood Cancers
    • Research in the Viswanath Lab – K. Viswanath, PhD, Lee Kum Kee Professor of Health Communication, Harvard T.H. Chan School of Public Health, Dana-Farber Cancer Institute, Director, Center for Translational Health Communication Science, Director, Harvard Chan India Research Center, and Co-Director, Lee Kum Sheung Center for Health and Happiness
    • Closing Remarks – William C. Hahn, MD, PhD, Executive Vice President and Chief Operating Officer, and William Rosenberg Professor of Medicine, Harvard Medical School

    Speaker Biographies

    Learn more about the Symposium's distinguished speakers.

    Contact Information

    For questions, please contact Aideen Mulligan, Chief of Staff to the Chief Scientific Officer: eadaoinn_mulligan@dfci.harvard.edu.

  • 75 Years

    75 Years. One Mission.

    As we mark Dana-Farber's 75-year anniversary, we can take pride that we are anchored by the core principles of Sidney Farber's mission: To make scientific discoveries and turn them into life-saving treatments.